TY - JOUR
T1 - Comparative performance analysis of interventional devices for the treatment of ischemic disease in below-the-knee lesions
T2 - a systematic review and meta-analysis
AU - Matsuoka, Emi Kearon
AU - Hasebe, Terumitsu
AU - Ishii, Ryota
AU - Miyazaki, Naoki
AU - Soejima, Kenzo
AU - Iwasaki, Kiyotaka
N1 - Funding Information:
KS has received personal fees as honoraria from AstraZeneca and has received research funding from AstraZeneca, Nippon Boehringer Ingelheim, and Taiho Pharmaceutical. All other authors have nothing to disclose.
Funding Information:
This work was supported in part by the Subsidy Program for Development of International Standards for Evaluation of Innovative Medical Devices and Regenerative Medicine Products, of the Ministry of Health, Labour and Welfare, Japan.
Publisher Copyright:
© 2021, The Author(s).
PY - 2022/1
Y1 - 2022/1
N2 - This meta-analysis aimed to evaluate the device performance of conventional balloon catheters (POBA), drug-coated balloons (DCB), bare-metal stents (BMS), and drug-eluting stents (DES) in below-the-knee (BTK) ischemic lesions with regard to lesion characteristics. Online searches of PubMed, Web of Science, and Cochrane databases (2010–2019) were conducted for each of the test devices. Primary patency rates (pp) and major amputation rates 1 year after the use of each device were analyzed using a random-effects meta-analysis model. Meta-regression analysis was conducted to test associations between the outcomes and lesion characteristics. The analysis included 18 studies reporting on 24 separate cohorts comprising 2,438 patients. DES demonstrated the best pp among the test devices (83.6%; 95% confidence interval = 78.4–88.8%, studies = 8; I2 = 66%, P = 0.005). A negative coefficient between lesion length and pp (P = 0.002) was obtained. The ratio of critical limb ischemia (CLI) patients impacted the amputation rates (P = 0.031), whereas no statistically significant difference was found between the devices. DES showed favorable pp in BTK lesions; however, as the lesion lengths using DES were short, pp in long lesions still needs to be evaluated. Shorter lesions gained better pp. A higher ratio of CLI patients resulted in increased amputation rates.
AB - This meta-analysis aimed to evaluate the device performance of conventional balloon catheters (POBA), drug-coated balloons (DCB), bare-metal stents (BMS), and drug-eluting stents (DES) in below-the-knee (BTK) ischemic lesions with regard to lesion characteristics. Online searches of PubMed, Web of Science, and Cochrane databases (2010–2019) were conducted for each of the test devices. Primary patency rates (pp) and major amputation rates 1 year after the use of each device were analyzed using a random-effects meta-analysis model. Meta-regression analysis was conducted to test associations between the outcomes and lesion characteristics. The analysis included 18 studies reporting on 24 separate cohorts comprising 2,438 patients. DES demonstrated the best pp among the test devices (83.6%; 95% confidence interval = 78.4–88.8%, studies = 8; I2 = 66%, P = 0.005). A negative coefficient between lesion length and pp (P = 0.002) was obtained. The ratio of critical limb ischemia (CLI) patients impacted the amputation rates (P = 0.031), whereas no statistically significant difference was found between the devices. DES showed favorable pp in BTK lesions; however, as the lesion lengths using DES were short, pp in long lesions still needs to be evaluated. Shorter lesions gained better pp. A higher ratio of CLI patients resulted in increased amputation rates.
KW - Bare-metal stent (BMS)
KW - Below-the-knee (BTK)
KW - Drug-coated balloon (DCB)
KW - Drug-eluting stent (DES)
KW - Meta-analysis
UR - http://www.scopus.com/inward/record.url?scp=85100577210&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100577210&partnerID=8YFLogxK
U2 - 10.1007/s12928-021-00758-7
DO - 10.1007/s12928-021-00758-7
M3 - Article
C2 - 33547627
AN - SCOPUS:85100577210
SN - 1868-4300
VL - 37
SP - 145
EP - 157
JO - Cardiovascular Intervention and Therapeutics
JF - Cardiovascular Intervention and Therapeutics
IS - 1
ER -